Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases by Chen, Jason A. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1186/s13024-018-0270-8
Link to publication record in King's Research Portal
Citation for published version (APA):
Chen, J. A., Chen, Z., Won, H., Huang, A. Y., Lowe, J. K., Wojta, K., ... Coppola, G. (2018). Joint genome-wide
association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to
neurodegenerative diseases. Molecular Neurodegeneration, 13(1), [41]. https://doi.org/10.1186/s13024-018-
0270-8
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
RESEARCH ARTICLE Open Access
Joint genome-wide association study of
progressive supranuclear palsy identifies
novel susceptibility loci and genetic
correlation to neurodegenerative diseases
Jason A. Chen1, Zhongbo Chen2, Hyejung Won3, Alden Y. Huang1, Jennifer K. Lowe3, Kevin Wojta4,
Jennifer S. Yokoyama5, Gilbert Bensimon6,7,8, P. Nigel Leigh9, Christine Payan6,7, Aleksey Shatunov2,
Ashley R. Jones2, Cathryn M. Lewis10, Panagiotis Deloukas11, Philippe Amouyel12, Christophe Tzourio13,
Jean-Francois Dartigues13, Albert Ludolph14, Adam L. Boxer5, Jeff M. Bronstein3, Ammar Al-Chalabi2,
Daniel H. Geschwind1,3 and Giovanni Coppola1,3,4,15*
Abstract
Background: Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease for which the genetic
contribution is incompletely understood.
Methods: We conducted a joint analysis of 5,523,934 imputed SNPs in two newly-genotyped progressive
supranuclear palsy cohorts, primarily derived from two clinical trials (Allon davunetide and NNIPPS riluzole trials in
PSP) and a previously published genome-wide association study (GWAS), in total comprising 1646 cases and 10,662
controls of European ancestry.
Results: We identified 5 associated loci at a genome-wide significance threshold P < 5 × 10− 8, including replication
of 3 loci from previous studies and 2 novel loci at 6p21.1 and 12p12.1 (near RUNX2 and SLCO1A2, respectively). At
the 17q21.31 locus, stepwise regression analysis confirmed the presence of multiple independent loci (localized
near MAPT and KANSL1). An additional 4 loci were highly suggestive of association (P < 1 × 10− 6). We analyzed the
genetic correlation with multiple neurodegenerative diseases, and found that PSP had shared polygenic heritability
with Parkinson’s disease and amyotrophic lateral sclerosis.
Conclusions: In total, we identified 6 additional significant or suggestive SNP associations with PSP, and discovered
genetic overlap with other neurodegenerative diseases. These findings clarify the pathogenesis and genetic
architecture of PSP.
Keywords: Genome-wide association study, Progressive supranuclear palsy, Neurodegeneration
Background
Tau pathology is a prominent hallmark of neurodegenerative
diseases, including Alzheimer’s disease (AD) and frontotem-
poral dementia (FTD). Progressive supranuclear palsy (PSP)
is a relatively pure tauopathy associated with parkinsonism -
dementia, characterized by pathological tau aggregation and
a clinical syndrome of postural instability, falls, and supra-
nuclear ophthalmoplegia [1]. It shares symptomatic and
neuropathologic overlap with a large group of diseases, that
are collectivity known as “tauopathies” due to characteristic
tau deposits; however, compared to these diseases, PSP
appears to be more clinically, neuropathologically, and genet-
ically homogenous [2–4]. Notably, the clinical syndrome has
high correlation with the neuropathology [5]. These charac-
teristics have thrust PSP into a central role for studying
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neurodegeneration, enabling clinical trials of a relatively
homogenous patient population with potentially more uni-
form response to treatment. Therefore, PSP has become a
target of intense clinical research [6, 7]. While the disease
shares neuropathological overlap with other tauopathies, the
polygenic genetic correlation with other neurodegenerative
diseases remains to be clarified.
The major known genetic risk factor is an extended
H1 haplotype on chromosome 17q21.31, which includes
MAPT (the gene encoding the tau protein), and is
homozygous in almost all PSP patients [2]. Other risk
factors identified include genome wide significant associ-
ations at loci near MAPT, MOBP, STX6, and EIF2AK3,
suggesting a strong contribution of common variation in
its genetic architecture [8]. We reasoned that the inclu-
sion of additional cases and controls could increase the
statistical power for genome-wide association, potentially
yielding novel loci that could provide insight into the
molecular mechanisms of PSP and other more common
tauopathies.
Methods
Cohort
Three cohorts of primarily European ancestry were in-
cluded in the study – “UCLA”, a combination of 349
PSP patients and 130 controls from the UCSF Memory
and Aging Center [2, 9] and the Allon Therapeutics
Davunetide trial [6]; “NNIPPS”, a group of 341 PSP pa-
tients from the Neuroprotection and Natural History in
Parkinson Plus Syndromes (NNIPPS) trial [7] and the
Blood Brain Barrier in Parkinson Plus syndromes
(BBBIPPS) study; and “Hoglinger”, 1112 PSP patients
from a previously published GWAS [8]. The UCLA co-
hort was divided into two, because of differences in
genotyping platform: “UCLA Omni 2.5” and “UCLA
HumanCore”. Further details are available in the Supple-
mentary Methods.
Genotyping
Genotyping in the UCLA study cohort was performed as
a prelude to whole-genome sequencing, and was per-
formed by Illumina (using the Illumina HumanOmni 2.5
Array) and the New York Genome Center (using the
Illumina HumanCore Array). Genotyping calls were
made using the Illumina GenomeStudio software.
Public datasets
Genotypes from the Hoglinger et al. GWAS [8] (cases
only – no controls) were obtained from the NIAGADS
database. Out-of-sample controls were obtained from
dbGAP Authorized Access to match each genotyping
platform. In total, for the HumanOmni 2.5 M platform, we
obtained 2364 subjects; for the OmniExpress platform, 870
subjects; and for the HumanQuad 660 W platform, 8756
subjects. For the Illumina HumanQuad 660 W Array
(Hoglinger et al. study), we used phs000103.v1.p1 “Genome--
Wide Association Studies of Prematurity and Its Complica-
tions”, phs000289.v1.p1 “National Human Genome Research
Institute (NHGRI) GENEVA Genome-Wide Association
Study of Venous Thrombosis”, phs000188.v1.p1 “Vanderbilt
Genome-Electronic Records (VGER) Project: QRS Dur-
ation”, phs000203.v1.p1 “A Genome-Wide Association Study
of Peripheral Arterial Disease”, phs000237.v1.p1 “Northwest-
ern NUgene Project: Type 2 Diabetes”, phs000234.v1.p1
“Group Health/UW Aging and Dementia eMERGE study”,
and phs000170.v1.p1 “A Genome-Wide Association Study
on Cataract and HDL in the Personalized Medicine Research
Project Cohort”. For the Illumina HumanOmni 2.5 Array
(UCLA – this study, and NNIPPS study), we used
phs000371.v1.p1 “Genetic Modifiers of Huntington’s Dis-
ease”, phs000429.v1.p1 “NEI Age-Related Eye Disease Study
(AREDS) - Genetic Variation in Refractive Error Substudy”,
and phs000421.v1.p1 “A Genome-Wide Association Study
of Fuchs’ Endothelial Corneal Dystrophy (FECD)”. For the
Illumina HumanCore Array (UCLA – this study), we used
the WTCCC2 cohort, which was typed on the related Illu-
mina OmniExpress Array. Subjects with an ascertained
phenotype (e.g., disease) were removed. More detailed in-
formation regarding these datasets is available in Add-
itional file 1: Table S1.
Data preprocessing
Genotypes for all datasets were converted to the forward
strand, and converted into coordinates based on the hg19
reference sequence using UCSC liftOver [10]. The genotypes
were then merged and pre-processed according to platform.
Determination of cryptic relatedness (pairwise proportion
IBD, PI-HAT > 0.2), sample missingness (> 0.05), genotype
missingness (> 0.05), Hardy-Weinberg equilibrium p-value
(< 10−5), and sex-matching was performed in PLINK
v1.90b3.28 [11] and used to quality-control (QC) samples
using standard parameters [12]. Ancestry was predicted by
multidimensional scaling based on raw Hamming distances,
implemented in PLINK. Only samples of presumed
European ancestry that clustered with known Europeans
from the HapMap3 cohort [13] were included. Preprocessing
steps are further elaborated in Additional file 2: Figure S1.
Imputation
Imputation was performed separately for each geno-
typing platform using the IMPUTE v2.3.2 algorithm
[14]. Prephasing of chromosomes using the Segmented
HAPlotype Estimation & Imputation Tool (SHAPEIT)
v2.r837 was performed as previously described [15, 16].
IMPUTE2 was run on the prephased haplotypes using the
1000 Genomes Project Phase 3 reference in non-overlapping
5 megabase chunks with a 250 kilobase buffer and an effect-
ive population size of 20,000. Imputed variants with an
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imputation genotype probability < 0.9, missingness > 0.05, or
minor allele frequency < 0.01 were removed, and genotypes
across platforms were merged. Cryptic relatedness across co-
horts was assessed, and related/duplicated samples were
removed.
Association
Association was performed using a linear mixed model to
correct for population structure, using BOLT-LMM [17].
The genotyping platform was used as a categorical covariate.
The standard infinitesimal model p-values were chosen for
downstream anaylsis. Odds ratios were calculated as exp.
(beta). Because some of the individual cohort sizes violate
the large sample size assumptions of BOLT-LMM, odds ra-
tios for association (for individual cohorts) were computed
using a logistic regression model in PLINK, using the first 5
eigenvectors, derived from Principal Component Analysis
(PCA), as covariates. Power calculations were performed
using the Genetic Power Calculator [18], assuming a variant
with risk allele frequency of 0.5 and relative risk of 1.3 in an
additive genetic model, a disease with a prevalence of 10 in
100,000, and a p-value threshold of 5 × 10− 8, using a geno-
typic, 2 df case-control test. QQ and Manhattan plots were
constructed using the R package “qqman” [19]. Forest plots
were constructed using the R package “metafor” [20]. The
genomic inflation factor λ was computed with PLINK.
Correction of the genomic inflation factor to an equivalent
sample size of 1000 cases and 1000 controls was performed
as previously described [21]. To control for the extended
haplotype on chr17q21 and to identify independent associ-
ation signals, we performed association as before, but includ-
ing the haplotype (tagged by the SNP rs1560310) [22] as a
covariate.
Proportion variance in liability explained
The explained variance in liability at each of the
genome-wide significant loci was calculated according to
the method of So et al., which requires the frequency of
the risk allele, the relative risk of the heterozygous geno-
type, the relative risk of the homozygous risk genotype,
and the prevalence of the disease in the population [23].
The allele frequencies were calculated from the control
population of the joint genotyping cohort. Relative risks
were approximated with the corresponding odds ratios,
which converges to relative risk when the prevalence of
disease is rare. Genotypic odds ratios were estimated by
assuming an additive model. The prevalence of PSP was
estimated at 6.5 per 100,000 in accordance with prior
epidemiological studies [24, 25]. The genome-wide poly-
genic variance in liability explained was calculated using
GCTA v1.24.7 [26]. The genetic relationship matrix was
calculated chromosome-by-chromosome and then
re-combined. The first 5 principal components were
calculated and used as covariates for restricted max-
imum likelihood (REML) analysis.
Prediction of gene expression differences associated with
PSP-associated SNPs
Genetic associations with PSP may be due to genetic
control of gene expression. We used TWAS to pre-
dict differential gene expression in PSP from the joint
analysis summary statistics, integrating paired geno-
typing and gene expression data from the GTEx
Consortium [27]. Correcting for approximately 5000
effective independent tests per brain region (taking
into account 5483 genes with significantly heritable
weights and the interdependence of gene expression,
particularly across tissues), the significance threshold
was set at P < 1 × 10− 5.
Credible set of causal variants at PSP GWAS loci
A credible set (potential causal variants) was identified
at each of total of seven genome-wide significant loci
identified in this study using the CAusal Variants Identi-
fication in Associated Regions (CAVIAR) software pack-
age [28]. Because of the extended linkage disequilibrium
patterns in the chromosome 17q21.31 haplotype region,
causal variants were not identified at this associated
locus. Within each of the selected loci, the SNP with the
minimum joint association p-value was chosen as the
index SNP, and variants with p-value < 10− 5 and in LD
(r2 > 0.6) with the index SNP were input into CAVIAR.
The CAVIAR-identified credible set contains potential
causal variants (with a confidence level of 95% under the
statistical model) that could explain the association at
each locus.
Identification of genes linked to credible SNPs with
chromatin interaction data
Genetic variation can result in changes to the coding se-
quence of a gene (e.g., nonsense and missense variants)
or can regulate the gene’s expression (e.g., by affecting
transcription factor binding in promoter or enhancer
regions). We first identified credible SNPs as “func-
tional” (stopgain variant, frameshift variant, splice donor
variant, nonsense-mediated decay transcript variant, or
missense variant). Of the remaining credible SNPs, we
identified those in the promoter region of a gene, de-
fined as the range 2 kb upstream to 1 kb downstream
relative to the transcription start site (TSS). Finally, the
remaining credible SNPs were considered possible regu-
latory variants and tested for short- or long- range inter-
action with other regions of chromatin to identify
potential downstream target genes. The interactions
were determined by Hi-C experiments in IMR90 and
embryonic stem cells from public data [29, 30], and fetal
brain germinal zone (ventricular and subventricular
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zone) and cortical plate (intermediate zone and marginal
zone) from our group [31].
Genetic correlation with neurodegenerative diseases
Genetic correlation was assessed from GWAS summary sta-
tistics using the Linkage Disequilibrium Score Regression
method (LDSC) [32]. Summary statistics were filtered by
only considering SNPs that overlap with the HapMap3 refer-
ence panel. Refer to the Supplementary Methods for further
details.
Data availability
Full and imputed genotyping results from the UCLA
and NNIPPS cohorts will be made available on the
NIAGADS database.
Results
We analyzed subjects from three GWAS cohorts, including
1) a multi-center cohort [2, 6] in whom we performed
genotyping using the Illumina HumanOmni2.5 BeadChip
and the Illumina HumanCore BeadChip (“UCLA”); 2) pa-
tients from centers in France, Germany, and the United
Kingdom as part of the Neuroprotection and Natural
History in Parkinson Plus Syndromes (NNIPPS) study, a
double-blind randomized placebo-controlled clinical trial of
riluzole [7], genotyped with the Illumina HumanOmni2.5
BeadChip (“NNIPPS”), and 3) a cohort of autopsy-proven
cases from a previously published [8] GWAS (“Hoglinger”).
A more detailed description of the cohorts is provided in
Additional file 1: Table S1. We combined each cohort with
platform-matched, out-of-sample controls from dbGAP
(Additional file 1: Table S1). Stringent QC – excluding
SNPs that had low genotype call rates (< 0.95) or did not
follow Hardy-Weinberg equilibrium, and excluding subjects
with low sample call rate (< 0.95), non-European ancestry,
incompatible sex, cryptic relatedness, or duplication across
cohorts (Additional file 2: Figure S1) – was applied to each
cohort (including platform-matched controls). We then im-
puted variants implementing IMPUTE2 [14] using the
1000 Genomes Phase 3 Reference Panel to estimate geno-
types at more than 77,000,000 SNPs. Imputed variants with
imputation quality scores (r2 < 0.9) or low minor allele
frequency (< 0.01) were filtered, and genotypes across all
cohorts were combined in a joint analysis. In total, we ex-
amined 6,419,662 SNPs in 1646 PSP cases and 10,662
controls.
Association was initially performed using the 616 cases
represented from the UCLA and NNIPPS cohorts.
Genome-wide significant association was detected at loci
near MAPT and largely corresponded to the haplotype
region (lead SNP rs79730878, p = 5.4 × 10− 45; Additional
file 1: Table S2). Other top associations were found at
loci near MOBP, STX6, SEMA4D, DDX27, and SP1,
though these did not reach genome-wide significance.
To increase statistical power, we combined all three
cohorts in a joint analysis framework. We estimated that
this combined cohort had 90% power to detect associ-
ation of a variant with allele frequency of 0.5 and relative
risk of 1.3. For a cohort of the sample size of that in a
previous PSP GWAS from Hoglinger et al., the power to
detect association was only 33%. In the primary analysis,
we assessed the genome-wide association between the
genotype at each SNP and case-control status using a
linear mixed model to correct for population stratifica-
tion. The genomic inflation factor λ for the joint analysis
was 1.05; for the UCLA-Omni2.5, UCLA-HumanCore,
NNIPPS, and Hoglinger cohorts, λ was 1.03, 1.02, 1.11,
and 1.11, respectively (Fig. 1, Additional file 2: Figure S2
and S3). We considered the joint inflation factor to be
acceptable in the setting of a relatively large joint ana-
lysis sample size [33]. Scaled for sample size, the ad-
justed genomic inflation factor λ1000 was 1.02.
The results of the joint analysis genome-wide association
are shown in Fig. 1 and Additional file 2: Figure S4. SNPs at
5 loci, in cytobands 17q21.31 (in an extended haplotype con-
taining MAPT, lead SNP rs71920662, odds ratio OR= 0.19,
p= 3.9 × 10− 113), 3p22.1 (within MOBP, rs10675541, OR=
0.71, p= 7.2 × 10− 19), 1q25.3 (within STX6, rs57113693, OR
= 1.3, p= 8.7 × 10− 16), 6p21.1 (within RUNX2, rs35740963,
OR= 0.77, p= 1.8 × 10− 8), and 12p12.1 (within SLCO1A2,
rs7966334, OR= 1.5, p= 3.2 × 10− 8), reached genome-wide
significance (p < 5 × 10− 8) (Additional file 1: Table S2,
Additional file 2: Figure S5). An additional SNP reported in a
previous GWAS [8], rs7571971, was also analyzed. Although
this SNP did not reach genome-wide significance in the joint
analysis (OR= 1.18, p= 2.7 × 10− 5), the direction of the asso-
ciation was consistent with the previous association in each
cohort. In order to decrease the likelihood that the results
were influenced by population stratification, we assessed
association at the loci in each of the study cohorts (Fig. 2).
Associations at the lead SNPs in each of the regions were
consistent across the three most well-powered study
cohorts (Hoglinger, NNIPPS, and UCLA Omni2.5)
while in general, the HumanCore subset of the UCLA
cohort was underpowered to detect association. An add-
itional 4 loci demonstrated suggestive association (1 × 10− 6
< P < 5 × 10− 8), in 1q41 (intergenic, near DUSP10,
rs12125383, OR = 1.28, p = 5.3 × 10− 8), 12q13.13 (within
SP1, rs147124286, OR = 0.74, p = 4.1 × 10− 7), 8q24.21
(within ASAP1, rs2045091, OR = 1.25, p = 4.7 × 10− 7), and
1p22.3 (nearWDR63 andMIR4423, rs114573015, OR = 2.1,
p = 5.9 × 10− 7) (Additional file 1: Table S3). Overall, the
genome-wide significant loci explained a combined 5.9% of
the variance in heritable liability of PSP (Additional file 1:
Table S4). The locus tagging the chr17q21 haplotype sur-
rounding MAPT contributed the majority (5.0%), while
new loci contributed an additional 0.2% of the total liability.
Using a polygenic model implemented in GCTA [26], the
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entire set of genotyped SNPs explains 9.4 ± 0.8% (estimate
±standard error) of the variance on the liability scale, sug-
gesting that many loci are yet to be found.
The association between PSP and the chr17q21 haplo-
type (H1/H2) has been widely characterized, but inde-
pendent SNPs in the chr17q21 region may also
contribute to disease susceptibility. To test this, we per-
formed linear regression, taking haplotype as a covariate.
Additionally, we identified subjects that were homozy-
gous for the risk allele (H1/H1), and performed associ-
ation in this subset of patients. Both approaches
identified similar independent associations from the H1
haplotype in the 17q21.31 region, with the most signifi-
cant SNPs at rs8078967 (P = 1.9 × 10− 14) and rs9904290
(P = 8.9 × 10− 12) in the haplotype-regressed and H1/H1
only datasets, respectively (Additional file 2: Figure S5).
These SNPs did not appear to be in strong linkage dis-
equilibrium with a previously reported SNP association,
rs242557 [8] (r2 = 0.008 and 0.007 in the 1000 Genomes
Project data – EUR super-population, respectively) that
was filtered from this dataset in variant QC; however,
they were highly correlated with each other (r2 = 0.996).
Additionally, both variants and rs242557 are within the
first intron of the MAPT gene.
To further understand how variation at each of the loci
contributes to disease risk, we assessed the functional con-
sequences of significant SNPs. We first identified a set of
potential causal SNPs using the CAVIAR method, which
identifies a “credible set” of SNPs that encompasses those
likely to be causal [28]. The 17q21.31 locus was excluded
from the analysis because of its unusual, long-range link-
age disequilibrium pattern. In some loci, potentially causal
coding variants were identified (in genome-wide signifi-
cant loci, at 6p21.1, in RUNX2, and at 12p12.1, in
SLCO1A2; and in suggestive loci, at 8q24.21, in ASAP1,
and at 12q13.13, in AMHR2; Additional file 1: Table S5).
Other SNPs in the credible set fell within regulatory re-
gions; we identified the gene associated with each SNP
using data from Hi-C experiments, mapping chromosome
conformation patterns on a genome-wide scale from four
human cell types (IMR-90 fetal lung fibroblasts, embry-
onic stem cells, fetal brain, and fetal brain germinal zone).
Each potential regulatory SNP in the credible set was then
associated with genes in close proximity by chromosomal
conformation, yielding potential downstream causal genes
(Additional file 1: Table S5).
To supplement the mapping information from Hi-C,
we also identified the functional consequences of GWAS
Fig. 1 Genome-wide SNP association in the joint analysis. a Manhattan plot indicating the SNP association P values. The vertical axis displays the
strength of association (−log10 P value) as a function of genomic position, with alternating colors for sequential chromosomes. Genome-wide
significant and suggestive loci are labeled with the nearest gene symbol. The thresholds for significant (P < 5 × 10− 8, red horizontal line) and
suggestive (P < 1 × 10− 6, blue horizontal line) associations are shown. b-d Quantile-quantile plots for: b all SNPs, including the strongly associated
extended haplotype on chromosome 17; c SNPs excluding chromosome 17; and d SNPs excluding genome-wide significant and suggestive loci.
The 95% confidence interval for the expected distribution of p-values is shaded
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Fig. 2 (See legend on next page.)
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hits using the TWAS method to predict genes that may
be affected by risk alleles [27]. TWAS estimates gene ex-
pression values using paired reference transcriptome/
genotyping datasets (e.g., for expression quantitative trait
loci - eQTL studies) and genotype information from
summary statistics, and predicts differential expression
between cases and controls. Using reference data from
the GTEx Consortium, TWAS predicted the effect of
gene expression from the risk haplotypes in multiple
tissues. At a threshold of P < 1 × 10− 5, we identified a
number of genes that were called as differentially
expressed (Additional file 1: Table S6). As expected due
to the length and lack of recombination in the region,
most of these genes (17) clustered around the chromo-
some 17 haplotype. Notably, MAPT (within the associ-
ated 17q21.31 locus) was among the genes predicted to
be differentially expressed, as well as STX6 (within the
associated 1q24 locus), SP1 (within the suggestive
12q13.13 locus), SKIV2L (within 6p21.33, nearby the as-
sociated 6p21.1 locus), and RPSA (within the associated
3p22.1 locus). Other genes that were pinpointed outside
of association regions were CEP57 (in 11q21) and
RPS6KL1 (in 14q24.3).
The strong neuropathological overlap of PSP with
other tauopathies suggests that genetic overlap may
exist. Using the LDSC software [32], we assessed genetic
overlap of PSP with other neurodegenerative diseases,
including AD, behavioral variant FTD (bvFTD), Parkin-
son’s disease (PD), and amyotrophic lateral sclerosis
(ALS), by using GWAS summary statistics. As controls,
we included summary statistics from GWAS for heritable,
non-neurodegenerative diseases of brain (schizophrenia
and bipolar disorder), a quantitative trait (height), and a
non-brain disease (type 2 diabetes) (for further details,
refer to the Supplementary Methods). Each of these traits
was shown to be heritable. Statistically significant genetic
correlations were identified for PD (P = 9.7 × 10− 5) and
ALS (P = 1.8 × 10− 3), but not for non-neurodegenerative
disease control GWAS (Fig. 3).
Discussion
As a prototypical tauopathy, insight into PSP susceptibility
alleles can help to illuminate the downstream molecular ef-
fects of tau pathology, which is a major component of
many common neurodegenerative diseases. Altogether,
from a joint analysis of three disease cohorts, we have
found 2 novel genome-wide significant susceptibility loci in
PSP and replicated 3 previously reported loci. Of the loci
identified in this study, three (within MAPT, MOBP, and
STX6) were reported significant in a previous GWAS [8].
In the MAPT region, a third independent association
was identified, also in MAPT intron 1, speculatively sug-
gesting important regulatory functions in this region;
however, no effects in differential expression have been
uncovered. Overall, the mechanisms of the MAPT asso-
ciations have been unclear. The larger H1/H2 haplotype
appears to affect splicing at MAPT exon 3 but not over-
all tau expression [34]; while other MAPT variants, such
as rs242557, may affect tau expression in some tissues
[35], the effect is not robust in brain tissue. The
additional association identified here may provide an or-
thogonal point of investigation into this curious region.
An additional locus near the EIF2AK3 gene (encoding
PERK, a key component of the unfolded protein re-
sponse) was also previously identified; however, the re-
ported SNP did not reach genome-wide significance in
this joint analysis or in the new “Hoglinger” cohort
(using different controls).
We also identified 2 novel genome-wide significant
susceptibility loci at 6p21.1 and 12p12.1 (near RUNX2
and SLCO1A2, respectively). At 6p21.1, we identified a
lead SNP as well as several coding SNPs in the credible
set within RUNX2, a gene thought to be a transcriptional
factor involved in regulation of osteoblastic differentiation
[36]. While seemingly unrelated to PSP, a curious number
of neurodegeneration-related genes are also involved in
bone diseases (e.g. TREM2, which has been linked to AD
and Nasu-Hakola disease [37, 38], and VCP, linked to
amyotrophic lateral sclerosis and Paget’s disease of bone
[39, 40]). At 12p12.1, we identified a lead SNP and credible
set coding SNPs within SLCO1A2, a transporter present
(among other places) at the blood-brain barrier, where it
regulates solute trafficking [41]. An additional four loci
(near the genes DUSP10, SP1, ASAP1, and WDR63/
MIR4423) were suggestive of association, but did not reach
genome-wide significance. While this study raises the possi-
bility of involvement of these genes in PSP pathogenesis,
further fine-mapping and functional studies are needed to
confirm their possible roles.
(See figure on previous page.)
Fig. 2 Forest plots showing association across each individual cohort for selected SNPs. A total of six genome-wide significant loci were
identified, with representative SNPs: a rs71920662 in 17q21.31, near MAPT; b rs57113693 in 1q25.3, near STX6; c rs10675541 in 3p22.1, near MOBP;
d rs35740963 in 6p21.1, near RUNX2; and e rs7966334 in 12p12.1, near SLCO1A2. An additional four suggestive loci were also identified: f
rs12125383 in 1q41, near DUSP10 in an intergenic region; g rs147124286 in 12q13.13, near SP1; h rs2045091 in 8q24.21, near ASAP1; and i
rs114573015 in 1p22.3, near WDR63. j Additionally, a previously reported GWAS SNP rs7571971 in 2p11.2, near EIF2AK3, was not identified as
genome-wide significant in the joint analysis
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Our results also implicate possible alternative causal
genes in previously reported genome-wide significant
loci. At 3p22.1, the gene closest to the GWAS lead SNP
was reported as MOBP. This locus has previously been
implicated in differential expression of the SLC25A38/
appoptosin gene, which may regulate tau cleavage [42].
Using Hi-C, we have identified chromatin interactions
with MYRIP and EIF1B that could also explain this asso-
ciation. Similarly, at 1q25.3, the gene closest to the
GWAS lead SNP was STX6; by Hi-C, we have also iden-
tified XPR1 as a possible candidate gene. Interestingly,
our group has previously demonstrated XPR1 mutations
in primary familial brain calcification [43], though any
mechanistic overlap with PSP is unclear. Analysis of eQTL
datasets (in GTEx) suggests that RPSA at 3p22.1 and
SKIV2L near 6p21.1 may also be the causal genes but the
tissue-relevant datasets were relatively underpowered.
Aside from identifying additional associated loci and
highlighting potential PSP susceptibility genes, we ana-
lyzed the polygenic overlap between neurodegenerative
diseases, identifying shared heritability with PD and ALS.
Curiously, these diseases do not have predominant tau
neuropathology, as PSP and other tauopathies do. Typic-
ally, PD is associated with aggregation of α-synuclein, and
ALS with aggregation of TDP43 and other proteins, while
tau pathology is prominent in AD. However, there are
known shared genetic risk factors among these diseases.
The 17q21.31 haplotype is highly associated with PD, in
the same direction as in PSP [44], and SNPs near the
MOBP gene have been recently associated with ALS [45].
Our results indicate the existence of common neurode-
generative disease pathways even across traditional protein
aggregate-based subdivisions, and could potentially lead to
effective treatment strategies.
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Fig. 3 Heatmap of genetic correlation between GWAS summary statistics for neurodegenerative diseases (PSP – progressive supranuclear palsy,
ALS – amyotrophic lateral sclerosis, AD – Alzheimer’s disease, bvFTD – behavioral variant frontotemporal dementia, PD – Parkinson’s disease),
calculated by LDSC. GWAS for non-neurodegenerative phenotypes (SCZ – schizophrenia, BIP – bipolar disorder, height, and T2D– type 2 diabetes
mellitus) are also included for comparison. In each cell, the genetic correlation coefficient (and P value in parentheses) is shown. Phenotypes that
share a common polygenic background are positively correlated
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A limitation of the study includes the case-control
matching design. While this design allows for matching by
array platforms and avoids stratification due to technical
artifacts, stratification based on the ancestral differences
may be present. The potential for stratification was
reduced by strict filtering based on multidimensional
scaling to limit the sample to subjects of European ances-
try, and linear mixed model methods to further reduce
confounding. Combining multiple cohorts as we have
done may also reduce the degree of population stratifica-
tion in the joint sample. Overall, the genomic inflation fac-
tor (λ = 1.05) suggested an acceptable level of population
stratification. The validity of the results and replication of
the original GWAS are further reinforced by the
consistency of the identified associations across the mul-
tiple platform-matched sub-cohorts.
Conclusion
Here, we have increased the number of significant
genetic risk locus for PSP, an important advance for
understanding its pathophysiology. The power of this
study to identify novel loci at genome wide signifi-
cance and a large unexplained heritability suggests
that PSP may be highly amenable to genetic associ-
ation studies in larger sample cohorts using next
generation sequencing. Overall, by establishing the
genetic correlations of PSP with PD and ALS and
identifying novel genome-wide significant and sug-
gestive associations, we shed insight into the mecha-
nisms of neurodegenerative disease.
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